Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (26562)	11/17/1998 9:06:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

I suspect that they are counting on significant milestones from LLY, which would be related to Targretin. There may also be income from a marketing deal.

To: jayhawk969 who wrote (26562)	11/17/1998 9:50:00 AM
From: Skeeter Bug	Read Replies (2) \| Respond to of 32384

>>I am embarrassed for Bear Stearns.<< me too. however, don't worry about them as they have no conscience. -ng- i hope they prove us to be dolts, though ;-)

To: jayhawk969 who wrote (26562)	11/17/1998 1:53:00 PM
From: Machaon	Read Replies (2) \| Respond to of 32384

<< ... anyone else expect approximately $20MM in milestones and/or other income >> The LGND/LLY Phase II trials for type II diabetes has been going on in Belgium and the Netherlands since March 1997. Perhaps Ligand "expected" royalties/milestones from this program?! Sure would be nice to see some preliminary data on this trial. Obviously they haven't stopped the trial early based on positive or negative results. It'll be two years this coming March, 1999.